Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.

Content Provider	Europe PMC
Author	Farhangnia, Pooya Ghomi, Shamim Mollazadeh Akbarpour, Mahzad Delbandi, Ali-Akbar
Copyright Year	2023
Abstract	Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers. Recently, BsAbs have represented a significant advancement in improving clinical outcomes. BsAbs are designed to target two different antigens specifically. Over a hundred various BsAb forms currently exist, and more are constantly being manufactured. An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P. Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). A promising strategy to overcome this hurdle is using BsAbs. This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.
Page Count	11
Journal	Frontiers in Immunology
Volume Number	14
PubMed Central reference number	PMC10333476
PubMed reference number	37441075
e-ISSN	16643224
DOI	10.3389/fimmu.2023.1155778
Language	English
Publisher	Frontiers Media S.A.
Publisher Date	2023-06-27
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Copyright © 2023 Farhangnia, Ghomi, Akbarpour and Delbandi
Subject Keyword	CTLA-4 (cytotoxic T lymphocyte-associated protein 4) CD152 bispecific antibody (BsAbs) cancer immunotherapy Bi-specific T cell engagers (BiTEs)
Content Type	Text
Resource Type	Article
Subject	Immunology Immunology and Allergy